Cargando…
Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer
Prostate cancer (PCa) is the second most common male cancer worldwide, but effective biomarkers for the presence or progression risk of disease are currently elusive. In a series of nine matched histologically confirmed PCa and benign samples, we carried out an integrated transcriptome-wide gene exp...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413154/ https://www.ncbi.nlm.nih.gov/pubmed/36033512 http://dx.doi.org/10.3389/fonc.2022.914078 |
_version_ | 1784775670826532864 |
---|---|
author | Mou, Zhuofan Spencer, Jack Knight, Bridget John, Joseph McCullagh, Paul McGrath, John S. Harries, Lorna W. |
author_facet | Mou, Zhuofan Spencer, Jack Knight, Bridget John, Joseph McCullagh, Paul McGrath, John S. Harries, Lorna W. |
author_sort | Mou, Zhuofan |
collection | PubMed |
description | Prostate cancer (PCa) is the second most common male cancer worldwide, but effective biomarkers for the presence or progression risk of disease are currently elusive. In a series of nine matched histologically confirmed PCa and benign samples, we carried out an integrated transcriptome-wide gene expression analysis, including differential gene expression analysis and weighted gene co-expression network analysis (WGCNA), which identified a set of potential gene markers highly associated with tumour status (malignant vs. benign). We then used these genes to establish a minimal progression-free survival (PFS)-associated gene signature (GS) (PCBP1, PABPN1, PTPRF, DANCR, and MYC) using least absolute shrinkage and selection operator (LASSO) and stepwise multivariate Cox regression analyses from The Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) dataset. Our signature was able to predict PFS over 1, 3, and 5 years in TCGA-PRAD dataset, with area under the curve (AUC) of 0.64–0.78, and our signature remained as a prognostic factor independent of age, Gleason score, and pathological T and N stages. A nomogram combining the signature and Gleason score demonstrated improved predictive capability for PFS (AUC: 0.71–0.85) and was superior to the Cambridge Prognostic Group (CPG) model alone and some conventionally used clinicopathological factors in predicting PFS. In conclusion, we have identified and validated a novel five-gene signature and established a nomogram that effectively predicted PFS in patients with PCa. Findings may improve current prognosis tools for PFS and contribute to clinical decision-making in PCa treatment. |
format | Online Article Text |
id | pubmed-9413154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94131542022-08-27 Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer Mou, Zhuofan Spencer, Jack Knight, Bridget John, Joseph McCullagh, Paul McGrath, John S. Harries, Lorna W. Front Oncol Oncology Prostate cancer (PCa) is the second most common male cancer worldwide, but effective biomarkers for the presence or progression risk of disease are currently elusive. In a series of nine matched histologically confirmed PCa and benign samples, we carried out an integrated transcriptome-wide gene expression analysis, including differential gene expression analysis and weighted gene co-expression network analysis (WGCNA), which identified a set of potential gene markers highly associated with tumour status (malignant vs. benign). We then used these genes to establish a minimal progression-free survival (PFS)-associated gene signature (GS) (PCBP1, PABPN1, PTPRF, DANCR, and MYC) using least absolute shrinkage and selection operator (LASSO) and stepwise multivariate Cox regression analyses from The Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) dataset. Our signature was able to predict PFS over 1, 3, and 5 years in TCGA-PRAD dataset, with area under the curve (AUC) of 0.64–0.78, and our signature remained as a prognostic factor independent of age, Gleason score, and pathological T and N stages. A nomogram combining the signature and Gleason score demonstrated improved predictive capability for PFS (AUC: 0.71–0.85) and was superior to the Cambridge Prognostic Group (CPG) model alone and some conventionally used clinicopathological factors in predicting PFS. In conclusion, we have identified and validated a novel five-gene signature and established a nomogram that effectively predicted PFS in patients with PCa. Findings may improve current prognosis tools for PFS and contribute to clinical decision-making in PCa treatment. Frontiers Media S.A. 2022-08-12 /pmc/articles/PMC9413154/ /pubmed/36033512 http://dx.doi.org/10.3389/fonc.2022.914078 Text en Copyright © 2022 Mou, Spencer, Knight, John, McCullagh, McGrath and Harries https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Mou, Zhuofan Spencer, Jack Knight, Bridget John, Joseph McCullagh, Paul McGrath, John S. Harries, Lorna W. Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title | Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title_full | Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title_fullStr | Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title_full_unstemmed | Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title_short | Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
title_sort | gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413154/ https://www.ncbi.nlm.nih.gov/pubmed/36033512 http://dx.doi.org/10.3389/fonc.2022.914078 |
work_keys_str_mv | AT mouzhuofan geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT spencerjack geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT knightbridget geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT johnjoseph geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT mccullaghpaul geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT mcgrathjohns geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer AT harrieslornaw geneexpressionanalysisrevealsa5genesignatureforprogressionfreesurvivalinprostatecancer |